Skip to main content

Grass Pollen Allergy

3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
3 programs
2
1
grass pollen allergen extractPhase 41 trial
Grass pollen formulationPhase 31 trial
grass pollen allergoidPhase 31 trial
Active Trials
NCT00264459Completed160Est. Sep 2011
NCT00263601Completed154Est. Aug 2010
NCT00841256Completed207Est. Aug 2015
Innovation Pharmaceuticals
1 program
Motivation-enhancing interventionN/A1 trial
Active Trials
NCT05560698Completed224Est. Jun 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergopharmagrass pollen allergen extract
AllergopharmaGrass pollen formulation
Allergopharmagrass pollen allergoid
Innovation PharmaceuticalsMotivation-enhancing intervention

Clinical Trials (4)

Total enrollment: 745 patients across 4 trials

NCT00841256Allergopharmagrass pollen allergen extract

Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children

Start: Feb 2008Est. completion: Aug 2015207 patients
Phase 3Completed
NCT00264459AllergopharmaGrass pollen formulation

Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

Start: Feb 2003Est. completion: Sep 2011160 patients
Phase 3Completed
NCT00263601Allergopharmagrass pollen allergoid

Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

Start: Nov 2001Est. completion: Aug 2010154 patients
Phase 3Completed
NCT05560698Innovation PharmaceuticalsMotivation-enhancing intervention

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment

Start: Sep 2022Est. completion: Jun 2024224 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.